Anti-TREM2 (extracellular)-PE

FC, LCI

Triggering receptor expressed on myeloid cells 2, Triggering receptor expressed on monocytes 2.

Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C

Lyophilized powder

Triggering receptor expressed on myeloid cells 2, Triggering receptor expressed on monocytes 2. - A Rabbit Polyclonal Antibody to TREM2 (extracellular) conjugated to the fluorescent dye Phycoerythrin (PE).

Mouse, human - 14 out of 15 amino acid residues identical; Rat - 12 out of 15 amino acid residues identical

Confirmed by amino acid analysis and mass spectrometry

1 mg/ml

Extracellular, N-terminus

Mouse

41116161

TREM2 (triggering receptor expressed on myeloid cells-2) is a type I transmembrane microglial surface receptor that is found to be expressed on myeloid cells including monocyte-derived dendritic cells, osteoclasts and bone-marrow derived macrophage. TREM2 protein transduces intracellular signals that regulate microglial functions such as cytokine production, migration, proliferation, phagocytosis, cell survival, synapse elimination, and compaction of amyloid plaques1, 2.The TREM2 structure includes an immunoglobulin-like extracellular domain responsible for ligand binding, a transmembrane region and a short cytoplasmatic tail. The protein also includes an ectodomain that binds anionic and zwitterionic lipids, apolipoproteins and lipoprotein particles2, 3.Studies show that TREM2 knockout mice display decreased levels of inflammatory cytokines. TREM2 has been shown to control two signaling pathways in the brain: regulation of phagocytosis and suppression of inflammatory reactivity. Nasu-Hakola disease, a rare and fatal disease, and polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy has been found to be linked to homozygous loss-of-function mutations in TREM2 protein1, 2. Studies also show that variants of TREM2 are associated with Alzheimer's disease2, 3.